Cabenuva Approval Expanded to Include Adolescents With HIV
The expanded approval was supported by data from studies in the adult population and by data from an interim analysis of the phase 1/2 MOCHA study.
The expanded approval was supported by data from studies in the adult population and by data from an interim analysis of the phase 1/2 MOCHA study.
Researchers evaluated first-line treatment with arthemether-lumefantrine plus amodiaquine in patients with uncomplicated Plasmodium falciparum malaria infection living in areas with an increased prevalence of multidrug-resistant parasites.
The approval was based on data from two phase 3 studies, which compared the safety and immunogenicity of PreHevbrio to Engerix-B in adults.
Researchers from the Centers for Disease Control and Prevention assessed the use of nifurtimox for the treatment of patients with American trypanosomiasis (Chagas disease).
Researchers conducted a systematic review to assess the effect of dolutegravir plus lamivudine on inflammatory and atherogenesis biomarkers in people with HIV infection.
In trials of ivermectin as a treatment for COVID-19, the relative risk of mortality varies with strongyloidiasis prevalence.
Investigators evaluated the 14-day bactericidal activity of various doses of meropenem, with or without rifampin, in patients being treated for pulmonary tuberculosis.
Researchers compared the incidence of intra-familial influenza transmission after treatment of the first family member with baloxavir marboxil vs oseltamivir.
Researchers evaluated the safety, effectiveness, and cardiotoxity risk associated with concomitant treatment with bedaquiline and delamanid in patients with multidrug-resistant tuberculosis infection.
A retrospective study was conducted to determine if enhanced external counterpulsation is an effective therapy for long-COVID.